Aytu Biopharma (AYTU) Other Non-Current Liabilities (2015 - 2026)

Aytu Biopharma (AYTU) has 12 years of Other Non-Current Liabilities data on file, last reported at $2.2 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $2.2 million, down 55.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (down 55.8% YoY), and the FY2025 annual result was $4.9 million, down 61.41% from the prior year.
• Other Non-Current Liabilities eased to $2.2 million in Q1 2026 per AYTU's latest filing, from $27.3 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $27.3 million in Q4 2025 and troughed at $2.2 million in Q1 2026.
• A 5-year average of $9.3 million and a median of $7.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities jumped 2824.76% in 2022, then plunged 61.41% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $9.8 million in 2022, then tumbled by 35.14% to $6.3 million in 2023, then grew by 0.66% to $6.4 million in 2024, then surged by 328.08% to $27.3 million in 2025, then slumped by 92.02% to $2.2 million in 2026.
• Business Quant data shows AYTU's Other Non-Current Liabilities at $2.2 million in Q1 2026, $27.3 million in Q4 2025, and $20.4 million in Q3 2025.